• 1
    Millikan R, Logothetis C. Update of the NCCN guidelines for treatment of prostate cancer. Oncology 1997; 11: 18092
  • 2
    Fowler FJ, Barry MJ, Lu-Yao G et al. Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. Urology 1995; 45: 100715
  • 3
    Fowler FJ, Barry MJ, Lu-Yao G et al. Outcomes of external beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology and end results areas. J Clin Oncol 1996; 14: 225865
  • 4
    Abrams PH, Griffith DJ. The assessment of prostatic obstruction from urodynamic measurements and from residual urine. Br J Urol 1979; 51: 12934
  • 5
    Barry MJ, Fowler FJ, O'Leary MP et al. and the measurement committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 154957
  • 6
    Lee WR, McQuellon RP, Harris-Henderson K, Case LD, McCullough DL. A preliminary analysis of health-related quality of life in the first year after permanent source interstitial brachytherapy (PIB) for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 46: 7781
  • 7
    Lilleby W, Fosså SD, Wæhre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43: 73543
  • 8
    International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy. ICRU Report 50. Bethesda, MD: 1993
  • 9
    Koper PCM, Stroom JC, Van Putten WLJ et al. Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study. Int J Radiat Oncol Biol Phys 1999; 43: 72734
  • 10
    Tait DM, Nahum AE, Meyer LC et al. Acute toxicity in pelvic radiotherapy. A randomised trial of conformal versus conventional treatment. Radiother Oncol 1997; 42: 12136
  • 11
    Pollack A, Zagars GK, Starkschall G et al. Conventional vs. conformal radiotherapy for prostate cancer. Preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 1996; 34: 55564
  • 12
    Farquharson DI, Shingleton HM, Sanford SP, Soong SJ, Varner RE Jr, , Hester S. The short-term effect of pelvic irradiation for gynecologic malignancies on bladder function. Obstet Gynecol 1987; 70: 814
  • 13
    Hanfmann B, Engels M, Dorr W. Radiation-induced impairment of urinary bladder function. Assessment of micturition Volumes. Strahlenther Onkol 1998; 174 (Suppl. 3): 968
  • 14
    Zelefsky MJ, Ginor RX, Fuks Z, Leibel SA. Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. International J Radiat Oncol Biol Phys 2002; :in press
  • 15
    Hamada K, Kihana T, Kataoka M et al. Urinary disturbance after therapy for cervical cancer. Urodynamic evaluation and beta2-agonist medication. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10: 36570


  1. Authors

V. Do, MBBS, FRANZCR, Radiation Oncologist.

R. Choo, MD, FRCPC, FACR, Radiation Oncologist.

G. DeBoer, PhD, Biostatistician.

S. Herschorn, MD, FRCSC, Urologist.

C. Danjoux, MD, FRCPC, Radiation Oncologist.

C.H. Chen, MRT (T), Radiation Therapist.

I. Barak, CCRA, Clinical Trials Assistant.




Quality of Life (assessment)


clinical target volume


planning target volume


postvoid residual volume.